Moving Towards Industry 5.0 in the Pharmaceutical Manufacturing Sector: Challenges and Solutions for Germany
本文通过文献综述和德国专家访谈，识别制药业采纳工业5.0的障碍，并用AHP-ELECTRE-DEMATEL方法排序，发现“连接虚拟与现实”是关键障碍，提出解决方案以帮助从业者理解并推动采纳。
Emergence of industry 5.0 facilitates real-time synchronisation of production processes, which helps with the production of customized products. Although industry 5.0 can revolutionize the landscape of goods production, still its adoption is in the infancy stage. Hence, the purpose of this article is to examine barriers that impede the adoption of industry 5.0, and to propose solution initiatives (SIs). After an in-depth literature review and interviews with German industry experts in pharmaceutical sector, barriers and SIs are ranked using an integrated Analytical hierarchy process-elimination and choice expressing reality-decision-making trial and evaluation laboratory (AHP-ELECTRE-DEMATEL) approach. “Linking virtual reality and reality” is found to be the most critical deterrent to the adoption of industry 5.0, and falls into a causal group, which signifies their influence on other deterrents. “Measures for better connectivity with patients” is of utmost importance for German firms to ensure secure communication and safeguard patient data. The findings also highlight the problems with the adoption of high-tech innovations due to lack of standardization and fair benchmarking policies on industry 5.0. This article concludes by proposing an industry 5.0 framework. The inhibitors to adopting industry 5.0 were investigated in this article, the results of which will assist practitioners and decision makers to understand the issues with industry 5.0. The results of this article will help potential adopters of this technology to look for the SIs. This will therefore pave the path for effective adoption of industry 5.0 across the pharmaceutical manufacturing sector.